[{"from": "human", "value": "Provide a description of this molecule. [C][C@H1][C@H1][Branch2][Ring2][#C][C][Branch2][Ring2][=Branch1][C][C][N][Branch1][Branch1][C][C][Ring1][=Branch1][C][=C][N][=C][Branch1][Branch2][C][=Branch1][Ring2][=N][Ring1][=Branch1][N][S][C][=C][Branch1][#Branch2][C][=Branch1][=Branch1][=N][C][=C][Ring1][=Branch1][N][Cl][C][O][Ring2][Ring1][#Branch2][N]"}, {"from": "gpt", "value": "The molecule is an inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration, SHP2 inhibitor TNO155 binds to and inhibits SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the RAS-RAF-ERK signaling pathway. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation."}]